Incretin-based therapies for the treatment of obesity-related diseases
Abstract Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and metabolic diseases (i.e. type 2 diabe...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Portfolio
2024-11-01
|
| シリーズ: | npj Metabolic Health and Disease |
| オンライン･アクセス: | https://doi.org/10.1038/s44324-024-00030-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|